Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentler concurrent chemoradiotherapy regimens for locally advanced and metastatic non-small cell lung cancer
ACTRN12606000519550Phase 2Completed
- Sponsor
- Bryan Burmeister
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vinorelbine, cisplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bryan Burmeister. Primary endpoints: Objective response rate, Symptomatic response rate and 2 more. Started Dec 2003; status: completed.
02
Drugs
vinorelbinecisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12606000519550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000519550.